| abstract |
FIELD: pharmaceutics. n SUBSTANCE: invention relates to the chemical and pharmaceutical industry, and more particularly to a pharmaceutical composition for preventing and treating HIV infection. Pharmaceutical composition contains a HIV protease inhibitor representing ritonavir and magnesium aluminometasilicate in a weight ratio of 1:(0.5–1.5). Magnesium aluminometasilicate is Neusilin ® . Ritonavir includes polymorphic form 1, polymorphic form 2, or combinations thereof. Pharmaceutical composition is prepared in solid form. n EFFECT: composition, according to the invention, using magnesium aluminometasilicate Neusilin ® provides close solubility characteristics, regardless of the polymorphic form of ritonavir used. n 9 cl, 1 tbl, 2 ex |